ReviewRespiratory research2026
Early detection and risk stratification in autoimmune-related interstitial lung disease: a state-of-the-art review.
Review in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interstitial lung disease (ILD) is a major pulmonary complication of autoimmune rheumatic diseases (ARD) and a leading contributor to long-term morbidity and mortality. Although ARDs share underlying immune dysregulation, the onset, radiologic phenotype, and clinical course of ILD vary substantially across individual diseases. Consequently, early detection and structured risk stratification at baseline and during follow-up have become essential elements of care for patients at risk of ARD-related ILD.This review examines the principles and emerging strategies for early identification of ARD-related ILD, emphasizing the role of systematic clinical assessment, high-resolution computed tomography, and longitudinal pulmonary function evaluation in detecting early lung involvement. We discuss how radiologic patterns, functional measures, and serological profiles contribute to prognostic classification in different autoimmune contexts, with particular focus on the early identification of patients at risk of rapid ILD progression. Disease-specific ILD patterns are reviewed across major autoimmune conditions—including systemic sclerosis, idiopathic inflammatory myopathies, primary Sjögren’s syndrome, mixed connective tissue disease, systemic lupus erythematosus, rheumatoid arthritis, and anti-neutrophil cytoplasmic antibody-associated vasculitis—each characterized by distinct risk factors, distinct imaging findings, and divergent prognostic trajectories. Finally, we highlight emerging approaches to risk stratification, including integrated models that combine clinical, radiologic, and serological domains to mitigate the risk of disease progression and guide monitoring strategies.Overall, current evidence supports a precision-medicine framework for ARD-related ILD, in which early recognition and individualized assessment of progression risk are crucial to improving outcomes and informing therapeutic decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.